Latest Safety News

Page 1 of 252
The US FDA has refused to lift the clinical hold on Argenica Therapeutics’ xaranetide stroke program, demanding a GLP rat neurotoxicity study and imposing a lower exposure limit than the company proposed for Phase 2b. Argenica plans to challenge parts of the assessment while pursuing regulatory submissions elsewhere.
Ada Torres
Ada Torres
19 Nov 2026
An independent interim analysis has confirmed statistically significant iPPS benefits in Paradigm’s rest-of-world knee osteoarthritis cohort, giving the company a possible route to continue development despite the overall trial failing its futility test. Any new trial remains subject to funding, creditor approval and regulatory discussions.
Ada Torres
Ada Torres
19 Nov 2026
Clarity Pharmaceuticals has completed final follow-up assessments for every participant in its registrational Phase III AMPLIFY trial of 64Cu-SAR-bisPSMA. Topline results from AMPLIFY and the related CLARIFY trial are expected in the first half of 2027, with the data intended to support US FDA applications.
Victor Sage
Victor Sage
19 Nov 2026
Actinogen Medical’s pivotal XanaMIA trial produced a mixed result: Xanamem showed a small, non-significant benefit across the full 247-patient population, but a prespecified older-patient analysis found a statistically significant difference in disease stabilisation. The company will continue its open-label extension, suspend future Phase 3 spending and seek development partners.
Victor Sage
Victor Sage
19 Nov 2026
Nufarm has delivered a sharp FY26 recovery in underlying earnings and cash generation, with leverage falling to 2.0 times despite a 7% revenue decline. The statutory loss, no ordinary dividend and ongoing restructuring show the turnaround remains unfinished.
Ada Torres
Ada Torres
19 Nov 2026
Australian Vintage says its FY26 turnaround has restored positive free cash flow excluding growth investments, while Poco Vino sales and international expansion gather pace. The wine group is targeting a return to net cash in FY27, but has also withdrawn its 2040 net-zero emissions target.
Victor Sage
Victor Sage
18 Nov 2026
Racura Oncology has cleared a key ethics hurdle for its pivotal EMILI trial of RC220 in relapsed or refractory acute myeloid leukaemia. The Phase 2b program is funded from existing cash, but efficacy, regulatory and funding tests still stand between the company and Phase 3.
Ada Torres
Ada Torres
18 Nov 2026
Black Bear Minerals has secured MSHA approval for alternative mine rescue arrangements at its Shafter Silver Project in Texas, opening a compliant pathway to underground exploration. The work is intended to support resource validation, a maiden JORC estimate and early mine planning, but exploration has not yet begun.
Maxwell Dee
Maxwell Dee
18 Nov 2026
Metallium has commissioned an upgraded Flash Joule Heating reactor in Texas for its first commercial technology-services program beyond metals recovery. The early-stage MXene campaign is funded by Environmental Clean Technologies and could generate up to US$1.4 million over 12 months while Metallium retains its reactor and process intellectual property.
Victor Sage
Victor Sage
18 Nov 2026
Atmos Energy has replaced its existing at-the-market share sale programme with a new facility capable of issuing up to US$1.7 billion of common stock. No shares have been sold under the new arrangement, but the programme gives the gas distributor another substantial source of funding for its infrastructure spending.
Maxwell Dee
Maxwell Dee
18 Nov 2026
North Carolina regulators have approved Duke Energy’s rate settlements, authorising billions of dollars of investment while reducing the revenue increases the utilities initially sought. New rules for large data centre customers add protection against early exits and network costs, but final revenue calculations remain outstanding.
Maxwell Dee
Maxwell Dee
17 Nov 2026
Orezone Gold delivered record third-quarter production of 59,674 ounces, with revenue of US$238.5 million and operating cash flow of US$71.1 million. The ASX-listed miner also cleared its Bomboré Phase I debt and completed the Stage 2A hard-rock expansion while maintaining 2026 production guidance.
Maxwell Dee
Maxwell Dee
17 Nov 2026

Browse the archive

Full archive